Numerous PSMA-targeting radiotracers have been developed for positron emission tomography (PET) and single-photon emission computed tomography (SPECT), resulting in several approved radiotracers both for diagnosis and therapy of PSMA-expressing prostate cancer [5]. Here, FOLH1 is linked to prostate carcinoma.